Loading data for PBMWW — first visit, this takes a few seconds.
Psyence Biomedical Ltd. (PBMWW)
NasdaqCM: PBMWW
· Real-Time Price · USD
0.02
+0.00 (0.00%)
At close: Sep 10, 2026, 6:59 PM
The price, the headline numbers and the latest news, in one place.
Psyence Biomedical Ltd. (PBMWW) Stock Price, Analysis & Data
No data available
| Bid | 0 |
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.94M |
| 1.73 | |
| n/a | |
| n/a | |
| n/a | |
| P/B (ttm) | 0.00 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 0 |
| Volume | 17,617 |
| Avg. Volume (20D) | n/a |
| Open | 0.02 |
| Previous Close | 0.02 |
| Day's Range | 0.02 - 0.02 |
| 52-Week Range | 0.02 - 0.02 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PBMWW
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc....
IPO Date Jul 17, 2026
Employees 12
Stock Exchange NasdaqCM
Ticker Symbol PBMWW
Website https://psyencebiomed.com
Financial Performance
In 2026, Psyence Biomedical's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -6.94M, a decrease of -785.56%.
Financial StatementsEarnings Surprise
Psyence Biomedical has released their quarterly earnings on Invalid Date:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.